<SEC-DOCUMENT>0001193125-25-026243.txt : 20250214
<SEC-HEADER>0001193125-25-026243.hdr.sgml : 20250214
<ACCEPTANCE-DATETIME>20250214060615
ACCESSION NUMBER:		0001193125-25-026243
CONFORMED SUBMISSION TYPE:	424B3
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20250214
DATE AS OF CHANGE:		20250214

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ALLURION TECHNOLOGIES, INC.
		CENTRAL INDEX KEY:			0001964979
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		ORGANIZATION NAME:           	08 Industrial Applications and Services
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B3
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-274564
		FILM NUMBER:		25622851

	BUSINESS ADDRESS:	
		STREET 1:		11 HURON DR STE 200
		CITY:			NATICK
		STATE:			MA
		ZIP:			01760
		BUSINESS PHONE:		508-647-4000

	MAIL ADDRESS:	
		STREET 1:		11 HURON DR STE 200
		CITY:			NATICK
		STATE:			MA
		ZIP:			01760

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ALLURION TECHNOLOGIES HOLDINGS, INC.
		DATE OF NAME CHANGE:	20230207
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B3
<SEQUENCE>1
<FILENAME>d826753d424b3.htm
<DESCRIPTION>424B3
<TEXT>
<HTML><HEAD>
<TITLE>424B3</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Filed Pursuant to Rule 424(b)(3)<BR>Registration No. 333-274564 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Prospectus Supplement No.&nbsp;19 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(To Prospectus
dated December&nbsp;15, 2023) </B></P> <P STYLE="font-size:24pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g826753g0213212842326.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ALLURION TECHNOLOGIES, INC. </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Up to 56,548,268 Shares of Common Stock </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus supplement no.
19 (this &#147;Prospectus Supplement&#148;) amends and supplements the prospectus dated December&nbsp;15, 2023 (as supplemented or amended from time to time, the &#147;Prospectus&#148;) which forms part of our Registration Statement on Form <FONT
STYLE="white-space:nowrap">S-1/A</FONT> (Registration Statement <FONT STYLE="white-space:nowrap">No.&nbsp;333-274564).</FONT> This Prospectus Supplement is being filed to update and supplement the information included or incorporated by reference in
the Prospectus with the information contained in our Current Report on Form <FONT STYLE="white-space:nowrap">8-K,</FONT> filed with the Securities and Exchange Commission (the &#147;SEC&#148;) on February&nbsp;13, 2025 (the <FONT
STYLE="white-space:nowrap">&#147;8-K&#148;).</FONT> Accordingly, we have attached the <FONT STYLE="white-space:nowrap">8-K</FONT> to this Prospectus Supplement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This Prospectus Supplement updates and supplements the information in the Prospectus and is not complete without, and may not be delivered or utilized except
in combination with, the Prospectus, including any amendments or supplements thereto. This Prospectus Supplement should be read in conjunction with the Prospectus, and if there is any inconsistency between the information in the Prospectus and this
Prospectus Supplement, you should rely on this Prospectus Supplement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our common stock is listed on The New York Stock Exchange (&#147;NYSE&#148;) under
the symbol &#147;ALUR&#148; and our public warrants are listed on the NYSE under the symbol &#147;ALUR.WS&#148;. On February&nbsp;12, 2025, the last quoted sale price for shares of our common stock as reported on the NYSE was $5.11 per share, and
the last quoted sale price for our public warrants as reported on the NYSE was $0.0425 per warrant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>We are an &#147;emerging growth
company&#148; under applicable federal securities laws and will be subject to reduced public company reporting requirements. </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><B>Investing in our securities
involves a high degree of risk. Before buying any securities, you should carefully read the discussion of the risks of investing in our securities in &#147;Risk Factors&#148; beginning on page 26 of the Prospectus. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of the securities to be
issued under the Prospectus or determined if the Prospectus is truthful or complete. Any representation to the contrary is a criminal offense. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>The date of this Prospectus Supplement is February&nbsp;13, 2025. </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM <FONT
STYLE="white-space:nowrap">8-K</FONT> </B></P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>CURRENT REPORT
</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to Section&nbsp;13 OR 15(d) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>of The Securities Exchange Act of 1934 </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Date of Report (Date of earliest event reported): February&nbsp;13, 2025 </B></P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>ALLURION TECHNOLOGIES, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact name of registrant as specified in its charter) </B></P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>Delaware</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B><FONT STYLE="white-space:nowrap">001-41767</FONT></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B><FONT STYLE="white-space:nowrap">92-2182207</FONT></B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(State or other jurisdiction</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>of incorporation)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Commission</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>File Number)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(IRS Employer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Identification No.)</B></P></TD></TR>
</TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>11 Huron Drive </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Natick, MA, 01760 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of Principal Executive Offices, including Zip Code) </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(508) <FONT STYLE="white-space:nowrap">647-4000</FONT> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Registrant&#146;s telephone number, including area code) </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>N/A </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Former name or
former address, if changed since last report) </B></P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below
if the Form <FONT STYLE="white-space:nowrap">8-K</FONT> filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Soliciting material pursuant to Rule <FONT STYLE="white-space:nowrap">14a-12</FONT> under the Exchange Act (17
CFR <FONT STYLE="white-space:nowrap">240.14a-12)</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><FONT STYLE="white-space:nowrap">Pre-commencement</FONT> communications pursuant to Rule <FONT
STYLE="white-space:nowrap">14d-2(b)</FONT> under the Exchange Act (17 CFR <FONT STYLE="white-space:nowrap">240.14d-2(b))</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><FONT STYLE="white-space:nowrap">Pre-commencement</FONT> communications pursuant to Rule <FONT
STYLE="white-space:nowrap">13e-4(c)</FONT> under the Exchange Act (17 CFR <FONT STYLE="white-space:nowrap">240.13e-4(c))</FONT> </P></TD></TR></TABLE>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Securities registered pursuant to Section&nbsp;12(b) of the Act: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Title of each class</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Trading</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Symbol(s)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Name of each exchange</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>on which registered</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">Common Stock, par value $0.0001 per share</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">ALUR</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">The New York Stock Exchange</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">Warrants to purchase 0.056818 shares of Common Stock for $202.50 per share</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">ALUR WS</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">The New York Stock Exchange</TD></TR>
</TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of
1933 (&#167;230.405 of this chapter) or Rule <FONT STYLE="white-space:nowrap">12b-2</FONT> of the Securities Exchange Act of 1934 <FONT STYLE="white-space:nowrap">(&#167;240.12b-2</FONT> of this chapter). </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Emerging growth company&#8194;&#9746; </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an emerging growth
company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&nbsp;13(a) of the Exchange Act.&#8194;&#9744;
</P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%" VALIGN="top" ALIGN="left"><B>Item&#8201;8.01.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Other Events </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On February&nbsp;13, 2025, Allurion Technologies, Inc. (the &#147;Company&#148;) issued a press release announcing that it is relaunching the Allurion Balloon
in France after the Agence Nationale de S&eacute;curit&eacute; du M&eacute;dicament (&#147;ANSM&#148;), the French regulatory authority, cleared the Company to resume sales, effective immediately. A copy of the press release is attached hereto as
Exhibit 99.1 and is incorporated herein by reference. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%" VALIGN="top" ALIGN="left"><B>Item&#8201;9.01.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Financial Statements and Exhibits </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(d) Exhibits </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="93%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" ALIGN="center"><B>Exhibit<BR>No.</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>Description</B></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Press Release dated February&nbsp;13, 2025.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>104</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Cover Page Interactive Data File (embedded within the Inline XBRL document).</TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
thereunto duly authorized. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="44%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="44%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"><B>ALLURION TECHNOLOGIES, INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Date: February&nbsp;13, 2025</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Brendan Gibbons</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Brendan Gibbons</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Chief Legal Officer</TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Allurion Relaunches in France </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>ANSM, the French
regulatory authority, clears Allurion to resume sales of the Allurion Balloon </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Company considering sites in France for clinical trial on combination
therapy of Allurion Balloon and <FONT STYLE="white-space:nowrap">GLP-1s</FONT> to prevent muscle loss </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">February&nbsp;13, 2025 08:30 AM Eastern
Standard Time </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">NATICK, Mass.&#151;(BUSINESS WIRE)&#151;Allurion Technologies, Inc. (&#147;Allurion&#148; or the &#147;Company&#148;) (NYSE: ALUR), a
company dedicated to ending obesity, today announced that it is relaunching the Allurion Balloon in France after ANSM, the French regulatory authority, cleared Allurion to resume sales. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;We are thrilled the Allurion Balloon will once again serve French patients as a clinically proven treatment for obesity,&#148; said Dr.&nbsp;Shantanu
Gaur, Founder and CEO of Allurion. &#147;Historically, France has been our top performing market representing approximately 15% of our revenue, and we are looking forward to ramping back up in the coming quarters. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;In parallel, as we expand our clinical research pipeline, we are also exploring with French clinics a trial to demonstrate how the Allurion Balloon may
be combined with <FONT STYLE="white-space:nowrap">GLP-1s</FONT> to solve one of the biggest problems in obesity: how to take <FONT STYLE="white-space:nowrap">GLP-1s</FONT> without losing muscle mass. A successful trial could lead to the development
of a gold-standard obesity treatment that counters one of the biggest side effects of <FONT STYLE="white-space:nowrap">GLP-1</FONT> therapies.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">According to a recent study, the prevalence of excess weight and obesity in France is approximately 47% and 17%, respectively.<SUP
STYLE="font-size:75%; vertical-align:top">1</SUP>&nbsp;While current-generation <FONT STYLE="white-space:nowrap">GLP-1s</FONT> have now launched in France, their use has primarily been indicated as a second-line treatment in patients with a body
mass index (BMI) of greater than or equal to 35 with careful attention to side effect management.<SUP STYLE="font-size:75%; vertical-align:top">2</SUP>&nbsp;Previous studies in patients undergoing <FONT STYLE="white-space:nowrap">GLP-1</FONT>
therapy have demonstrated reductions in lean mass of approximately 40% as a proportion of total weight lost.<SUP STYLE="font-size:75%; vertical-align:top">3</SUP> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In contrast, in previous studies, patients treated with the Allurion Balloon in combination with the Allurion Virtual Care Suite have demonstrated strong
patient outcomes in which patients lose weight while maintaining, and in some cases, increasing, muscle mass. In one study of 571 patients, patients treated with the Allurion Balloon gained 5.6% in lean body mass while losing 14% of their total body
weight over four months.<SUP STYLE="font-size:75%; vertical-align:top">4</SUP>&nbsp;In another study of 167 patients, patients treated with the Allurion Balloon experienced a weight reduction of 15.7% with no change in muscle mass. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;We intend to initiate clinical trials designed to assess whether the Allurion Balloon combined with <FONT STYLE="white-space:nowrap">GLP-1s</FONT>
offers superior outcomes to <FONT STYLE="white-space:nowrap">GLP-1</FONT> therapies alone,&#148; continued Gaur. &#147;We intend for our first clinical trials to study muscle mass in a combination approach, but we expect to announce other clinical
trials in the future that will study dose reduction of <FONT STYLE="white-space:nowrap">GLP-1s</FONT> as a means to reduce side effects and increase adherence.&#148; </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Allurion </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Allurion is dedicated to ending obesity. The Allurion Program is a weight-loss platform that combines the Allurion Gastric Balloon, the world&#146;s first and
only swallowable, procedure-less<SUP STYLE="font-size:75%; vertical-align:top">TM</SUP>&nbsp;gastric balloon for weight loss, the Allurion Virtual Care Suite, including the Allurion Mobile App for consumers and Allurion Insights for healthcare
providers featuring the Iris AI Platform, and the Allurion Connected Scale. The Allurion Virtual Care Suite is also available to providers separately from the Allurion Program to help customize, monitor, and manage weight-loss therapy for patients
regardless of their treatment plan. The Allurion Gastric Balloon is an investigational device in the United States. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For more information about Allurion
and the Allurion Virtual Care Suite, please visit&nbsp;www.allurion.com. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Forward-Looking Statements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This press release contains certain forward-looking statements within the meaning of the U.S. federal and state securities laws. These forward-looking
statements generally are identified by the words &#147;believe,&#148; &#147;project,&#148; &#147;expect,&#148; &#147;consider,&#148; &#147;anticipate,&#148; &#147;estimate,&#148; &#147;intend,&#148; &#147;strategy,&#148; &#147;future,&#148;
&#147;opportunity,&#148; &#147;plan,&#148; &#147;target,&#148; &#147;may,&#148; &#147;should,&#148; &#147;will,&#148; &#147;would,&#148; &#147;will be,&#148; &#147;will continue,&#148; &#147;will likely result,&#148; &#147;if,&#148; and similar
expressions and include statements regarding Allurion&#146;s plan to initiate a clinical trial to assess the combination of the Allurion Program and <FONT STYLE="white-space:nowrap">GLP-1s,</FONT> the ability of the Allurion Program to help patients
achieve more metabolically healthy weight loss, the ability to launch future clinical studies focused on dose reduction of <FONT STYLE="white-space:nowrap">GLP-1s</FONT> as a means to reduce side effects and increase adherence, the ramping up of
Allurion&#146;s sales of the Allurion Balloon in France, and other statements about future events that reflect the current beliefs and assumptions of Allurion&#146;s management based on information currently available to them and, as a result, are
subject to risks and uncertainties. Forward-looking statements are predictions, projections and other statements about future events that reflect the current beliefs and assumptions of Allurion&#146;s management based on information currently
available to them and, as a result, are subject to risks and uncertainties. Many factors could cause actual future results or developments to differ materially from the forward-looking statements in this press release, including but not limited to
(i)&nbsp;the ability of Allurion to obtain regulatory approval for and successfully commercialize the Allurion Program, (ii)&nbsp;the timing of and results from its clinical studies and trials, (iii)&nbsp;the evolution of the markets in which
Allurion competes and the rise of <FONT STYLE="white-space:nowrap">GLP-1</FONT> drugs, (iv)&nbsp;the ability of Allurion to defend its intellectual property and satisfy regulatory requirements, (v)&nbsp;the impact of the Russia-Ukraine war and
Israel-Hamas war on Allurion&#146;s business, (vi)&nbsp;Allurion&#146;s expectations regarding its market opportunities, (vii)&nbsp;the outcome of any legal proceedings against Alurion, (viii)&nbsp;the risk of economic downturns and a changing
regulatory landscape in the highly competitive industry in which Allurion operates, and (ix)&nbsp;the ability of Allurion to obtain sufficient funding to initiate and/or complete any clinical studies that demonstrate positive results. The foregoing
list of factors is not exhaustive. You should carefully consider the foregoing factors and the other risks and uncertainties described in the &#147;Risk Factors&#148; section of the Company&#146;s Annual Report on Form
<FONT STYLE="white-space:nowrap">10-K</FONT> filed on March&nbsp;26, 2024 and Amendment No.&nbsp;1 thereto filed on April&nbsp;29, 2024, the Company&#146;s Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> filed on
November&nbsp;13, 2024 and other documents filed by Allurion from time to time with the U.S. Securities and Exchange Commission. These filings identify and address other important risks and uncertainties that could cause actual events and results to
differ materially from those contained in the forward-looking statements. Forward-</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and Allurion assumes no obligation and does not intend
to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. Allurion does not give any assurance that it will achieve its expectations. </P>
<P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:75%; vertical-align:top">1</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Fontbonne et al.<I>&nbsp;J. Clin. Med.</I>&nbsp;2023, 12(3), 925;&nbsp;https://doi.org/10.3390/jcm12030925
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:75%; vertical-align:top">2</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">https://ansm.sante.fr/actualites/analogues-du-glp-1-et-obesite-nous-prenons-des-mesures-pour-securiser-leur-utilisation-en-france?
</FONT></FONT></FONT></FONT></FONT></FONT></FONT></FONT></FONT> </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:75%; vertical-align:top">3</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Wilding et al.<I>&nbsp;NEJM.</I><I></I>&nbsp;2021, 384, <FONT STYLE="white-space:nowrap">989-1002;</FONT>
10.1056/NEJMoa2032183 </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:75%; vertical-align:top">4</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Dejeu et al.<I>&nbsp;Clin. Pract.</I>&nbsp;2024,<I>&nbsp;14</I>(3),
<FONT STYLE="white-space:nowrap">765-778;&nbsp;https://doi.org/10.3390/clinpract14030061</FONT> </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Contacts </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Media and Investors </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Hannah Lindberg </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">hlindberg@allurion.com </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g826753g0213212842326.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g826753g0213212842326.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  \ 1T# 2(  A$! Q$!_\0
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M7&A3/F:Q;S(03UB8_P!&S_WT*K_'W_D#Z-_U\2?^@BI2M*QK.7-2N<Q\"/\
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IR7%E;2R$8W21*Q_,BI;>UM[2,QVT$4*$Y*QH%!/KQ5N6EC*-.T^8_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
